Navigation Links
Before the Bell Scans: Hologic Inc., St. Jude Medical Inc., ResMed Inc., and Navidea Biopharmaceuticals Inc.
Date:8/30/2013

LONDON, August 30, 2013 /PRNewswire/ --

The U.S. equity market advanced on Thursday, August 29, 2013. All three benchmark indexes edged higher, with the Dow Jones Industrial Average gaining 0.11%, S&P 500 gaining 0.20%, and the NASDAQ Composite advancing 0.75%. Shares in the medical appliances and equipment companies ended on a mixed note as the broader market edged higher. The major movers in the sector included Hologic Inc. (NASDAQ: HOLX), St. Jude Medical Inc. (NYSE: STJ), ResMed Inc. (NYSE: RMD), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). All these companies are tracked by AAAResearchReports.com. Free technical research on HOLX, STJ, RMD, and NAVB can be downloaded upon sign up at:

http://www.aaaresearchreports.com/register/  

On Thursday, Hologic Inc.'s stock closed 0.60% lower at $21.57 after oscillating between $21.39 and $21.72. A total of 1.85 million shares were traded, which is less than its daily average volume of 3.26 million. The company's stock has gained 6.94% in last three months, outperforming the S&P 500 which has lost 0.62% during the same period. Moreover, the company's shares are trading above their 50-day and 200-day moving averages. Sign up today to read free research report on HOLX at:

http://www.AAAResearchReports.com/HOLX083013.pdf

Shares in St. Jude Medical Inc. fluctuated between gains and losses on Thursday before closing the day nearly flat. The company's shares traded between $50.12 and $50.93 before ending the day 0.02% lower at $50.60. A total of 0.63 million shares traded, which is below the daily average volume of 1.84 million. The company's stock has gained 14.43% in the last three months, outperforming the S&P 500 which has fallen by 0.62% during the same period. Additionally, St. Jude Medical Inc.'s stock is trading above its 50-day and 200-day moving averages. Register to download free technical analysis on STJ at:

http://www.AAAResearchReports.com/STJ083013.pdf

ResMed Inc.'s shares posted modest gains on Thursday. The company's shares traded between $47.92 and $48.46 before finishing the day 0.06% higher at $48.23. A total of 0.66 million shares were traded, which is below the daily average volume of 1.09 million. The company's shares have gained 4.51% in the last one month, outperforming the S&P 500 which has lost 2.80% during the same period. Furthermore, ResMed Inc.'s stock is currently trading above its 50-day and 200-day moving averages. A free report on RMD can be accessed by registering at:

http://www.AAAResearchReports.com/RMD083013.pdf

Shares in Navidea Biopharmaceuticals Inc. moved higher on Thursday, extending their gains from previous trading sessions. The company's shares ended the day at $2.99, up 1.01%, after oscillating between $2.91 and $3.01. A total of 0.29 million shares were traded, which is below the daily average volume of 0.68 million. The company's stock is up 26.16% in the last three months, outperforming the S&P 500 which has lost 0.62% during the same period. Additionally, Navidea Biopharmaceuticals Inc.'s stock is trading above its 50-day and 200-day moving averages. Register with AAA Research Reports and download the research on NAVB for free at:

http://www.AAAResearchReports.com/NAVB083013.pdf

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA ® charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

www.AAAresearchreports.com


'/>"/>
SOURCE AAA Research Reports
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. United Therapeutics Corporation to Announce Second Quarter 2013 Financial Results Before Market Open on Thursday, July 25, 2013
2. Before the Bell Scans: Pharmacyclics, United Therapeutics, Impax Laboratories, and Star Scientific
3. Grab the Summer Promo Before It Cools Down by Conscires Agile Practices
4. A Simple Guide to De-Risking Before Full Prescribing Information, New Life Science Webinar Hosted by Xtalks
5. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
6. United Therapeutics Corporation To Announce Fourth Quarter And Annual 2012 Financial Results Before Market Open On Tuesday, February 26, 2013
7. Wysebridge Encourages Taking The Patent Bar Before Major Exam Changes Are Implemented
8. United Therapeutics Corporation To Announce Third Quarter 2012 Financial Results Before Market Open On Thursday, November 1, 2012
9. United Therapeutics Corporation to Announce Second Quarter 2012 Financial Results Before Market Open on Thursday, July 26, 2012
10. Hologic to Showcase 3D Mammography (Breast Tomosynthesis) and Other Advanced Womens Imaging Technologies at RSNA 2011, the Largest Radiology Show in the World
11. First Warning Systems, Inc., Retains Joshua D.I. Ellenhorn, M.D., as Principal Investigator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017  BioPharmX Corporation (NYSE MKT: BPMX), ... dermatology market, today reported financial results for the ... will provide an update on the company,s clinical ... "We are pleased to report that last ... said President Anja Krammer. "We achieved key clinical ...
(Date:3/23/2017)... March 23, 2017 According to a report ... derivatives market is fragmented due to the presence of a large pool ... Thermo Fisher , and Sigma-Aldrich, compete with each other in ... collectively, held more than 76% of this market in 2016.  ... As of now, a ...
(Date:3/22/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a ... Biobank and GSK to generate genetic sequence data from the ... will enable researchers to gain valuable insights to support advances ... of serious and life threatening diseases. ... Genetic evidence has revolutionized ...
(Date:3/22/2017)... Mass. , March 22, 2017 Good ... that it has eclipsed the 130 million covered lives ... Blue Shield of Texas . With ... the Company continues to enjoy strong payor acceptance based ... its clinical programs and genetic counseling, its industry-leading customer ...
Breaking Biology Technology:
(Date:2/26/2017)... 2017  Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring, announces the appointment ... "Too often, too many offenders return to ... are trying to tackle this ongoing problem and ... family members. While significant steps are underway, Securus continues ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
Breaking Biology News(10 mins):